416 related articles for article (PubMed ID: 30850491)
1. Intention-to-Treat Analysis of
Schwenck J; Olthof SC; Pfannenberg C; Reischl G; Wegener D; Marzec J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
J Nucl Med; 2019 Oct; 60(10):1359-1365. PubMed ID: 30850491
[TBL] [Abstract][Full Text] [Related]
2.
Marzec J; Becker J; Paulsen F; Wegener D; Olthof SC; Pfannenberg C; Schwenck J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
Acta Oncol; 2020 Feb; 59(2):149-156. PubMed ID: 31559880
[No Abstract] [Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
5. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
[TBL] [Abstract][Full Text] [Related]
6. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by
Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S
World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995
[TBL] [Abstract][Full Text] [Related]
7.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract][Full Text] [Related]
8.
Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
[TBL] [Abstract][Full Text] [Related]
9. The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of
Metser U; Chua S; Ho B; Punwani S; Johnston E; Pouliot F; Tau N; Hawsawy A; Anconina R; Bauman G; Hicks RJ; Weickhardt A; Davis ID; Pond G; Scott AM; Tunariu N; Sidhu H; Emmett L
J Nucl Med; 2019 Sep; 60(9):1253-1258. PubMed ID: 30902875
[TBL] [Abstract][Full Text] [Related]
10.
Artigas C; Flamen P; Charlier F; Levillain H; Wimana Z; Diamand R; Albisinni S; Gil T; Velthoven RV; Peltier A; Gestel DV; Roumeguere T; Otte FX
World J Urol; 2019 Aug; 37(8):1535-1542. PubMed ID: 30824985
[TBL] [Abstract][Full Text] [Related]
11.
Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
[TBL] [Abstract][Full Text] [Related]
12. Detection Rate of
Jilg CA; Drendel V; Rischke HC; Beck TI; Reichel K; Krönig M; Wetterauer U; Schultze-Seemann W; Meyer PT; Vach W
J Nucl Med; 2019 Jul; 60(7):971-977. PubMed ID: 30683768
[TBL] [Abstract][Full Text] [Related]
13. Comparison of
Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
[TBL] [Abstract][Full Text] [Related]
14.
Habl G; Sauter K; Schiller K; Dewes S; Maurer T; Eiber M; Combs SE
Prostate; 2017 Jun; 77(8):920-927. PubMed ID: 28317152
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of whole-body MRI and
Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
[TBL] [Abstract][Full Text] [Related]
16. 3-Year Freedom from Progression After
Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P
J Nucl Med; 2020 Jun; 61(6):866-872. PubMed ID: 31676727
[No Abstract] [Full Text] [Related]
17. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
18. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
[TBL] [Abstract][Full Text] [Related]
19. Comparison Between
Cantiello F; Crocerossa F; Russo GI; Gangemi V; Ferro M; Vartolomei MD; Lucarelli G; Mirabelli M; Scafuro C; Ucciero G; De Cobelli O; Morgia G; Damiano R; Cascini GL
Clin Genitourin Cancer; 2018 Oct; 16(5):385-391. PubMed ID: 29937067
[TBL] [Abstract][Full Text] [Related]
20. Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy.
Bashir U; Tree A; Mayer E; Levine D; Parker C; Dearnaley D; Oyen WJG
Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):901-907. PubMed ID: 30617554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]